Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial

Key Points

• This research aims to evaluate the efficacy and safety of telitacicept in patients with IgA nephropathy.
• Phase 3 randomized trial assessing telitacicept dosage and outcomes in IgA nephropathy patients.
• Interim analysis conducted to gauge treatment response and safety parameters.
• Preliminary findings indicate significant reduction in proteinuria with telitacicept treatment.
• Safety profile is consistent with previous studies, with no new safety signals observed.